menu
    • menu
    [{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ADX-626","moa":"Coagulation factor XI","graph1":"Undisclosed","graph2":"Phase I","graph3":"ADARx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ADARx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ADARx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ADX-324","moa":"PKK","graph1":"Genetic Disease","graph2":"Phase III","graph3":"ADARx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"ADARx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ADARx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"Avance Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ADX-324","moa":"PKK","graph1":"Genetic Disease","graph2":"Phase III","graph3":"ADARx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"ADARx Pharmaceuticals \/ Avance Clinical","highestDevelopmentStatusID":"10","companyTruncated":"ADARx Pharmaceuticals \/ Avance Clinical"},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Series C Financing","leadProduct":"ADX-324","moa":"PKK","graph1":"Genetic Disease","graph2":"Phase III","graph3":"ADARx Pharmaceuticals","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.20000000000000001,"dosageForm":"Injection","sponsorNew":"ADARx Pharmaceuticals \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"ADARx Pharmaceuticals \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Series B Financing","leadProduct":"ADX-324","moa":"PKK","graph1":"Genetic Disease","graph2":"Phase III","graph3":"ADARx Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"ADARx Pharmaceuticals \/ Ascenta Capital","highestDevelopmentStatusID":"10","companyTruncated":"ADARx Pharmaceuticals \/ Ascenta Capital"},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ADX-324","moa":"PKK","graph1":"Genetic Disease","graph2":"Phase III","graph3":"ADARx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"ADARx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ADARx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"ADARx Pharmaceuticals | Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ADX-038","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"ADARx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ADARx Pharmaceuticals \/ ADARx Pharmaceuticals | Novotech","highestDevelopmentStatusID":"7","companyTruncated":"ADARx Pharmaceuticals \/ ADARx Pharmaceuticals | Novotech"},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ADX-038","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"ADARx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ADARx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ADARx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ADX-038","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ADARx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ADARx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ADARx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"ADARx Pharmaceuticals | Avance Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ADX-850","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"ADARx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ADARx Pharmaceuticals \/ ADARx Pharmaceuticals | Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"ADARx Pharmaceuticals \/ ADARx Pharmaceuticals | Avance Clinical"},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"SR One Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"ADARx Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"ADARx Pharmaceuticals \/ SR One Capital Management","highestDevelopmentStatusID":"5","companyTruncated":"ADARx Pharmaceuticals \/ SR One Capital Management"},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"ADARx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ADARx Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"2","companyTruncated":"ADARx Pharmaceuticals \/ AbbVie Inc"}]

    Find Clinical Drug Pipeline Developments & Deals by ADARx Pharmaceuticals

    Menu

    ADARx Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ADARx Pharmaceuticals

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            ADARx Pharmaceuticals

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADX-626

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1 Study of ADX-626 in Healthy Participants

                            Details : ADX-626 is a Oligonucleotide drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            July 23, 2025

                            Lead Product(s) : ADX-626

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ADARx Pharmaceuticals

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            ADARx Pharmaceuticals

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADX-038

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

                            Details : ADX-038 is a drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Glomerulonephritis, IGA.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 25, 2025

                            Lead Product(s) : ADX-038

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ADARx Pharmaceuticals

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            ADARx Pharmaceuticals

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADX-038

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 2 Study of ADX-038 in Participants with Geographic Atrophy

                            Details : ADX-038 is a drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Wet Macular Degeneration.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 25, 2025

                            Lead Product(s) : ADX-038

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ADARx Pharmaceuticals

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            ADARx Pharmaceuticals

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            AbbVie Dives Further Into siRNA With $335M Upfront in ADARx Deal

                            Details : The collaboration will leverage ADARx's RNA discovery expertise and proprietary siRNA technology to develop siRNA therapeutics across multiple disease areas, including immunology and oncology.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $335.0 million

                            May 14, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ADARx Pharmaceuticals

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            ADARx Pharmaceuticals

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADX-324

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            STOP-HAE: A Phase 3 Study of ADX-324 in HAE

                            Details : ADX-324 is a Oligonucleotide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Angioedemas, Hereditary.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            May 07, 2025

                            Lead Product(s) : ADX-324

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ADARx Pharmaceuticals

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            ADARx Pharmaceuticals

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADX-850

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : ADARx Pharmaceuticals | Avance Clinical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension

                            Details : ADX-850 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hypertension.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 16, 2024

                            Lead Product(s) : ADX-850

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : ADARx Pharmaceuticals | Avance Clinical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            ADARx Pharmaceuticals

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            ADARx Pharmaceuticals

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADX-324

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Bain Capital Life Sciences

                            Deal Size : $200.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            ADARx Pharmaceuticals, a Leader in Next Generation RNA Therapeutics, Announces Oversubscribed $200 Million Ser...

                            Details : The net proceeds will advance ADARx clinical programs including ADX-324, a siRNA designed to reduce the production of PKK, a protein critical to the etiology of hereditary angioedema, and ADX-038, under development for the treatment of paroxysmal nocturn...

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            August 09, 2023

                            Lead Product(s) : ADX-324

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Bain Capital Life Sciences

                            Deal Size : $200.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            ADARx Pharmaceuticals

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            ADARx Pharmaceuticals

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADX-038

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I/ Phase II

                            Sponsor : ADARx Pharmaceuticals | Novotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PN...

                            Details : ADX-038 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Hemoglobinuria, Paroxysmal.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 25, 2023

                            Lead Product(s) : ADX-038

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : ADARx Pharmaceuticals | Novotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            ADARx Pharmaceuticals

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            ADARx Pharmaceuticals

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADX-324

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Avance Clinical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients

                            Details : ADX-324 is a Oligonucleotide drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Angioedemas, Hereditary.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            January 20, 2023

                            Lead Product(s) : ADX-324

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Avance Clinical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            ADARx Pharmaceuticals

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            ADARx Pharmaceuticals

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADX-324

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Ascenta Capital

                            Deal Size : $46.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            ADARx Pharmaceuticals Raises $46 Million as Lead Product Enters the Clinic

                            Details : The net proceeds will be used to advance ADARx’s proprietary RNA targeting platform together with novel oligonucleotide delivery technologies and to initiate phase I clinical trial of ADX-324 (siRNA duplex oligonucleotide), for the treatment of heredit...

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            January 20, 2023

                            Lead Product(s) : ADX-324

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Ascenta Capital

                            Deal Size : $46.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth